Insider Selling: ASP Isotopes (NASDAQ:ASPI) CFO Sells 80,000 Shares of Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CFO Heather Kiessling sold 80,000 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $5.80, for a total value of $464,000.00. Following the completion of the sale, the chief financial officer directly owned 732,500 shares in the company, valued at approximately $4,248,500. This represents a 9.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ASP Isotopes Stock Down 0.9%

ASPI stock traded down $0.05 on Monday, reaching $5.71. 4,472,245 shares of the company traded hands, compared to its average volume of 5,221,891. The firm has a fifty day simple moving average of $7.31 and a 200-day simple moving average of $8.51. The company has a market cap of $632.90 million, a P/E ratio of -4.39 and a beta of 3.42. ASP Isotopes Inc. has a one year low of $3.65 and a one year high of $14.49. The company has a debt-to-equity ratio of 1.04, a current ratio of 6.14 and a quick ratio of 6.10.

ASP Isotopes (NASDAQ:ASPI) last released its earnings results on Wednesday, November 19th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.05). ASP Isotopes had a negative return on equity of 190.44% and a negative net margin of 1,259.12%.The company had revenue of $4.89 million during the quarter, compared to the consensus estimate of $2.25 million. Research analysts anticipate that ASP Isotopes Inc. will post -0.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ASPI shares. Loop Capital set a $15.00 target price on shares of ASP Isotopes in a report on Monday, October 27th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $11.00 price objective on shares of ASP Isotopes in a research report on Monday, November 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a report on Monday, December 22nd. Finally, Cantor Fitzgerald began coverage on ASP Isotopes in a report on Thursday, December 4th. They set an “overweight” rating and a $13.00 price target on the stock. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, ASP Isotopes presently has a consensus rating of “Hold” and an average target price of $13.00.

Hedge Funds Weigh In On ASP Isotopes

Several hedge funds and other institutional investors have recently modified their holdings of the company. ProShare Advisors LLC increased its position in ASP Isotopes by 12.4% during the third quarter. ProShare Advisors LLC now owns 13,101 shares of the company’s stock valued at $126,000 after acquiring an additional 1,448 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of ASP Isotopes by 41.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company’s stock valued at $40,000 after purchasing an additional 1,600 shares during the period. Mercer Global Advisors Inc. ADV increased its position in shares of ASP Isotopes by 8.3% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,056 shares of the company’s stock valued at $203,000 after purchasing an additional 1,622 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of ASP Isotopes by 9.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,840 shares of the company’s stock valued at $153,000 after purchasing an additional 1,878 shares during the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of ASP Isotopes by 30.4% in the 3rd quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock worth $81,000 after purchasing an additional 1,953 shares during the period. 16.80% of the stock is owned by institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.